Last updated: March 25, 2026
What is the Drug Identified by NDC 00527-3284?
NDC 00527-3284 corresponds to Provenge (Sipuleucel-T), an autologous cellular immunotherapy approved by the FDA in 2010 for metastatic castration-resistant prostate cancer (mCRPC). It is produced by Dendreon Corporation.
Current Market Landscape
Sales Performance and Demand
- 2019-2022 Revenue Trend: Provenge sales declined from approximately $120 million in 2019 to around $80 million in 2022, reflecting competitive pressure and payer access issues.
- Market Share: It holds a niche market in mCRPC, competing primarily with hormonal therapies, chemotherapies, and emerging immunotherapies such as pembrolizumab.
- Patient Demographics: Predominantly prescribed in the U.S. for men with asymptomatic or minimally symptomatic metastatic prostate cancer, with a typical treatment course involving multiple infusions over several weeks.
Competitive Environment
- Alternative Therapies: Second-line treatments including enzalutamide, abiraterone, and chemotherapy agents like docetaxel.
- Emerging Treatments: Checkpoint inhibitors and combination immunotherapy agents showing potential to replace or complement Provenge.
Regulatory and Reimbursement Challenges
- Payer reimbursement remains cautious, impacting patient access. CMS coverage varies, with some restrictions on patient eligibility.
- Reimbursement prices for Provenge average around $93,000 to $100,000 per treatment course, but actual net prices can be lower after discounts and rebates.
Price Projections (2023–2027)
Factors Influencing Pricing
- Patent expirations and biosimilar entry are unlikely within the next five years for Provenge, given its unique autologous manufacturing process.
- Payer negotiations could pressure list price reductions.
- Industry trend toward value-based pricing emphasizes treatment outcomes over high list prices.
Estimated Price Trends
| Year |
Estimated Average Price per Treatment Course |
Notes |
| 2023 |
$93,000 |
Stable, barring significant policy changes. |
| 2024 |
$92,000 |
Slight decline due to payer pressure. |
| 2025 |
$90,000 |
Continued market normalization. |
| 2026 |
$88,000 |
Potential further discounts with increased access. |
| 2027 |
$87,000 |
Market stabilization at lower price point. |
Market Dynamics Impacting Price
- Manufacturing costs remain high due to personalized production, limiting the ability to cut prices significantly.
- Reimbursement policies may lead to tiered or restricted access, impacting overall sales volume.
- Competitive advances could pressure prices downward if alternative treatments demonstrate comparable or superior efficacy.
Future Outlook
- The overall market for Provenge will likely shrink in terms of volume due to better-tolerated, more convenient, and lower-cost alternatives.
- Pricing will adjust downward gradually, driven by payer negotiations and market share losses.
- Entry of biosimilars is unlikely within the forecast period, maintaining the exclusivity of Provenge.
Key Takeaways
- Provenge has a niche but declining market, with revenues dropping over recent years.
- Prices are stable in the short term, averaging around $93,000 per course, with a gradual decrease forecasted.
- Market dynamics, including reimbursement policies and competitive therapies, limit pricing power.
- Long-term value-based care models may further drive down prices or lead to utilization declines.
- The lack of biosimilar competition preserves some pricing power but does not prevent prices from decreasing.
FAQs
1. Is Provenge likely to face biosimilar competition soon?
No. The autologous nature and manufacturing complexity of Provenge make biosimilar development challenging within the next five years.
2. How does payer coverage affect Provenge pricing?
Payer restrictions and reimbursement negotiations influence real-world net prices, often leading to discounts below list prices.
3. Are there new therapies threatening Provenge’s market share?
Emerging immunotherapies and targeted agents are reducing its share but not replacing it due to differing mechanisms and approved indications.
4. What is the main driver of cost for Provenge?
Manufacturing personalized cell therapies incurs high costs, limiting price reductions despite market pressures.
5. Could policy changes significantly alter revenue and pricing?
Yes. Payer shifts toward value-based reimbursement or policy reforms favoring cost-effective treatments could further compress prices.
References:
- Dendreon Corporation. (2022). Provenge (sipuleucel-T) product monograph.
- IQVIA. (2022). U.S. prescription drug sales and market reports.
- Centers for Medicare & Medicaid Services. (2023). Coverage policies for cancer immunotherapies.
- MarketWatch. (2023). Oncology immunotherapy market analysis.
- EvaluatePharma. (2023). Oncology drug market projections.
